Abstract
Population studies reveal HLA class I and class II gene polymorphisms associated with all the common chronic autoimmune diseases, notably spondylarthropathies, rheumatoid arthritis, multiple sclerosis and type I diabetes. We here discuss the exceptionally high levels of nucleotide diversity in the MHC region likely to reflect not only balancing selection acting on the epitope binding sites but also natural selection operating on the promoter region. The latter possibility is supported by functional studies with promoters, higher levels of diversity in the promoters of class II than class I genes and the relatively high frequency of single nucleotide polymorphisms around transcription factor binding sites. This, we argue, reflects the need for an appropriate level of signalling at the immunological synapse. We here summarise our knowledge of HLA promoter polymorphisms and how these translate into differential expression, T cell polarisation and inflammation. We discuss current strategies for pharmaceutical intervention in HLA expression.
Keywords: Promoter polymorphism, differential expression
Current Pharmaceutical Design
Title: The Role of HLA Promoters in Autoimmunity
Volume: 12 Issue: 29
Author(s): Brigitte Muller-Hilke and N. Avrion Mitchison
Affiliation:
Keywords: Promoter polymorphism, differential expression
Abstract: Population studies reveal HLA class I and class II gene polymorphisms associated with all the common chronic autoimmune diseases, notably spondylarthropathies, rheumatoid arthritis, multiple sclerosis and type I diabetes. We here discuss the exceptionally high levels of nucleotide diversity in the MHC region likely to reflect not only balancing selection acting on the epitope binding sites but also natural selection operating on the promoter region. The latter possibility is supported by functional studies with promoters, higher levels of diversity in the promoters of class II than class I genes and the relatively high frequency of single nucleotide polymorphisms around transcription factor binding sites. This, we argue, reflects the need for an appropriate level of signalling at the immunological synapse. We here summarise our knowledge of HLA promoter polymorphisms and how these translate into differential expression, T cell polarisation and inflammation. We discuss current strategies for pharmaceutical intervention in HLA expression.
Export Options
About this article
Cite this article as:
Muller-Hilke Brigitte and Mitchison N. Avrion, The Role of HLA Promoters in Autoimmunity, Current Pharmaceutical Design 2006; 12 (29) . https://dx.doi.org/10.2174/138161206778559759
DOI https://dx.doi.org/10.2174/138161206778559759 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Restless Legs Syndrome in Children: A Review and Update on Pharmacological Options
Current Pharmaceutical Design Biologics in Inflammatory and Immunomediated Arthritis
Current Pharmaceutical Biotechnology Clinical Applications of Non-Antimicrobial Actions of Tetracyclines in Inflammatory Diseases
Current Drug Therapy Iron-related Biomarkers in the Diagnosis and Management of Iron Disorders
Current Medicinal Chemistry Insight into the Epigenetics of Alzheimer's Disease: A Computational Study from Human Interactome
Current Alzheimer Research Weight Bearing Joints Destruction In Rheumatoid Arthritis
Current Rheumatology Reviews Molecular Targets of FoxP3+ Regulatory T Cells
Mini-Reviews in Medicinal Chemistry Midkine in Inflammatory and Toxic Conditions
Current Drug Delivery Fused Azolo-Quinoxalines: Candidates for Medicinal Chemistry. A Review of their Biological Applications
Current Medicinal Chemistry Finding a Place for Interleukin-1 Inhibitors in the Treatment of Rheumatologic Diseases
Current Pharmaceutical Design Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?
Cardiovascular & Hematological Disorders-Drug Targets Recent Drug-Repurposing-Driven Advances in the Discovery of Novel Antibiotics
Current Medicinal Chemistry The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews Biologics for the Treatment of Juvenile Idiopathic Arthritis
Current Medicinal Chemistry Phytochemical Characterization of Prickly Pear (Opuntia spp.) and of its Nutritional and Functional Properties: A Review
Current Nutrition & Food Science Arthropathy in Patients with CREST Variant Scleroderma
Current Rheumatology Reviews Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience The Tight Relationship Between Osteoclasts and the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Clinical Significance of Cytokines and Chemokines in Neuropsychiatric Systemic Lupus Erythematosus
Current Rheumatology Reviews